Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.
1. A method of manufacture, the method comprising:
culturing a bacterial composition anaerobically in a culturing medium to produce a first pure bacterial culture, wherein the bacterial composition comprises a first bacterial strain derived from a pathogen-free stool sample of a healthy human donor, and wherein the first bacterial strain is a member of the phylum Firmicutes;
lyophilizing bacteria from the first pure bacterial culture in the presence of an antioxidant;
mixing the lyophilized bacteria from the first bacterial culture with lyophilized bacteria from a second pure bacterial culture to produce a bacterial mixture, wherein the lyophilized bacteria from the second pure bacterial culture comprise a second bacterial strain of the phylum Firmicutes; and
encapsulating the bacterial mixture in a capsule, wherein the capsule is configured to deliver a pharmaceutical composition comprising the bacterial mixture and the antioxidant to a human subject's small intestine.
2. The method of claim 1 , further comprising testing the viability of the lyophilized bacteria from the first bacterial culture.
3. The method of claim 2 , further comprising testing the viability of the lyophilized bacteria from the second bacterial culture.
4. The method of claim 1 , wherein the second bacterial culture is a pure culture comprising the second bacterial strain.
5. The method of claim 1 , wherein an oxygen scavenging material is used to promote or preserve an anaerobic condition for the culturing, lyophilizing, or encapsulating.
6. The method of claim 1 , wherein the second bacterial strain is derived from the pathogen-free stool sample of the healthy human donor.
7. The method of claim 1 , wherein the pharmaceutical composition comprises trehalose.
8. The method of claim 1 , wherein at least one of the first and second bacterial strains comprises anaerobic bacteria.
9. The method of claim 1 , wherein the culturing of both the first and the second bacterial cultures occurs in an anaerobic environment.
10. The method of claim 9 , wherein the anaerobic environment is substantially devoid of oxygen.
11. The method of claim 9 , wherein the anaerobic environment contains at least one of nitrogen, carbon dioxide and hydrogen.
12. The method of claim 9 , further comprising culturing a second bacterial composition in an anaerobic environment to produce the second bacterial culture.
13. The method of claim 1 , wherein the antioxidant comprises cysteine.
14. A method of manufacture, the method comprising:
culturing an anaerobic bacterial strain in a culturing medium under substantially oxygen-free conditions to produce a bacterial culture, wherein the anaerobic bacterial strain is isolated from a stool sample of a healthy human donor, and wherein the anaerobic bacterial strain is Bacteroides or a member of the phylum Firmicutes; and
lyophilizing bacteria from the bacterial culture in the presence of a cryoprotectant and an antioxidant.
15. The method of claim 14 , wherein the substantially oxygen-free conditions contain at least one of nitrogen, carbon dioxide and hydrogen.
16. The method of claim 14 , wherein the cryoprotectant comprises trehalose.
17. The method of claim 16 , wherein the antioxidant comprises cysteine.
18. The method of claim 14 , wherein the antioxidant comprises cysteine.